Abstracts Archive - Page 896 of 2607 - ACR Meeting Abstracts

Abstract Number: 0894 • ACR Convergence 2020
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Stanley Cohen¹, Justus Fiechtner², Philip Mease³, Jeffrey Kaine⁴, Arthur Kavanaugh⁵, Yi-Lin (Irene) Cheng⁶, Claire Chou⁶, Ting-Ying Cheng⁷, Shih-Yao Lin⁶ and Mark Genovese⁸, ¹University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ²Michigan State University, Grand Rapids,, MI, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Sarasota Arthritis Research Center, Sapphire, NC, ⁵UC San Diego Health System, San Diego, CA, ⁶AltruBio, Taipei, Taiwan (Republic of China), ⁷AltruBio, Redwood City, CA, ⁸Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
Abstract Number: 0895 • ACR Convergence 2020
Effects of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19-Subunit of Interleukin-23, on Dactylitis and Enthesitis in Patients with Active Psoriatic Arthritis: Pooled Results Through Week 24 from Two Phase 3 Studies
Dennis McGonagle¹, Iain McInnes², Atul Deodhar³, Georg Schett⁴, Philip Mease⁵, May Shawi⁶, Shelly Kafka⁷, Chetan Karyekar⁸, Alexa Kollmeier⁹, Elizabeth Hsia¹⁰, Xie Xu¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Christopher Ritchlin¹³ and Proton Rahman¹⁴, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Global Services, LLC, Toronto, ON, Canada, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹¹Janssen Research & Development, LLC, San Marcos, CA, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ¹⁴Memorial University of Newfoundland, Department of Medicine, St John's, Canada
Background/Purpose: Guselkumab (GUS), a novel monoclonal antibody that specifically binds to the p19-subunit of IL-23, demonstrated efficacy in the Ph 3 DISCOVER-1 (D1) & DISCOVER‑2…
Abstract Number: 0896 • ACR Convergence 2020
Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs
Iain McInnes¹, William Tillett², Philip Mease³, Kurt de Vlam⁴, Louis Bessette⁵, Ralph Lippe⁶, Anna Maniccia⁷, Patrick Zueger⁷, Dai Feng⁷, Koji Kato⁸ and Andrew Östör⁹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc, North Chicago, IL, ⁹Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Xenofon Baraliakos¹, Annette Szumski², Kenneth Kwok³ and Bonnie Vlahos⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²Syneos Health, Princeton, ³Pfizer, New York, NY, ⁴Pfizer, Collegeville, PA
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…
Abstract Number: 0898 • ACR Convergence 2020
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Julie Birt¹, Michael Grabner², Keith Isenberg³, Theresa Hunter⁴, Chia-Chen Teng², Mingyang Shan¹, Jeffrey Lisse¹, Jianmin Wu¹, Kirstin Griffing¹ and Jeffrey R Curtis⁵, ¹Eli Lilly and Company, Indianapolis, IN, ²Healthcore, Inc, Wilmington, DE, ³Anthem, Inc, Indianapolis, IN, ⁴Eli Lilly and Company, Indianapolis, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year associated with advanced therapy (AT) initiation among…
Abstract Number: 0899 • ACR Convergence 2020
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Denis Poddubnyy¹, Effie Pournara², Agnieszka Zielinska³, Asta Baranauskaite⁴, Alejandro Muñoz Jiménez⁵, Sanchayita Sadhu⁶, Barbara Schulz², Michael Rissler², Chiara Perella² and Helena Marzo-Ortega⁷, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Medycyna Kliniczna, Warszawa, Poland, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ⁶Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁷The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
Abstract Number: 0900 • ACR Convergence 2020
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
Denis Poddubnyy¹, Xavier Juanola², Clément Prati³, Hagen Russ⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Mani Haschemi Nassab⁴ and Jean Dudler⁶, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain, ³Service de Rhumatologie, Hôpital Jean-Minjoz , Besançon, France, Besançon, France, ⁴Eli Lilly and Company, Indianapolis, Indiana, USA, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Rheumatology, HFR Fribourg - Hospital Cantonal, Fribourg, Switzerland, Fribourg, Switzerland
Background/Purpose: The efficacy of ixekizumab (IXE), a selective interleukin-17A antagonist, was assessed in patients (pts) with axial SpA (axSpA) in three Phase 3, randomized, double-blind,…
Abstract Number: 0901 • ACR Convergence 2020
Proinflammatory Neutrophil Function Is Modulated During Secukinumab Therapy in Psoriatic Arthritis Without Compromising Host Defence
Robert Moots¹, Andy Cross², Helen Wright², Steven Edwards², Nicola Goodson³, Jenny Hawkes³, Ayren Mediana¹ and Helen Frankland¹, ¹Liverpool University Hospitals, Liverpool, United Kingdom, ²University of Liverpool, Liverpool, United Kingdom, ³University of Liverpool, Liverpool
Background/Purpose: Secukinumab is a monoclonal antibody that neutralises IL-17A, which plays a key role in the IL-23/17A axis underlying the pathophysiology of psoriatic arthritis (PsA). …
Abstract Number: 0902 • ACR Convergence 2020
Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting
Maria Martin-Lopez¹, Beatriz Joven² and Jose Luis Pablos¹, ¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested…
Abstract Number: 0903 • ACR Convergence 2020
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset
Sabina Ciciriello¹, Tegan Smith², Geoffrey Littlejohn³, Kathleen Tymms⁴, David Mathers⁵, Helen Cooley⁶, Hedley Griffiths⁷, Catherine OSullivan² and Peter Youssef⁸, ¹Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia
Background/Purpose: In Australia the cost of biologic/targeted synthetic DMARDs (b/tsDMARDs) for treatment of PsA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 0904 • ACR Convergence 2020
Response to Ixekizumab by C-reactive Protein Level in Patients with Radiographic Axial Spondyloarthritis: Results from the COAST-V (Biological-Naïve) and COAST-W (TNF Inhibitor-Experienced) Trials at 52 Weeks
John Reveille¹, Proton Rahman², David Sandoval³, Talia Muran³, Andris Kronbergs³, Rebecca Bolce³, Vladimir Geneus³, Theresa Hunter³, Soyi Liu-Leage⁴, Martin Rudwaleit⁵, Jose Maldonado-Cocco⁶ and Filip Van den Bosch⁷, ¹Department of Internal Medicine, University of Texas, Houston, TX, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Eli Lilly and Company, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ⁶University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ⁷Ghent University Hospital, Ghent, Belgium
Background/Purpose: Tumor necrosis factor inhibitors (TNFis) are effective treatments for radiographic axial spondyloarthritis (r-axSpA), but may be less effective in patients (pts) without elevated C-reactive…
Abstract Number: 0905 • ACR Convergence 2020
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Frank Behrens⁷, Sven Richter⁸, Michele Brunori⁹, Lichen Teng⁸, Benoit Guerette⁸ and Josef Smolen¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸Amgen Inc., Thousand Oaks, ⁹Amgen Europe GmbH, Rotkreuz, Switzerland, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh…
Abstract Number: 0906 • ACR Convergence 2020
Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study
Atul Deodhar¹, Laure Gossec², Philip Mease³, Jason Coarse⁴, Heather Edens⁵, Natasha de Peyrecave⁶, Deepak Assudani⁶, Barbara Ink⁷ and Christopher Ritchlin⁸, ¹Oregon Health & Science University, Portland, OR, ²Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Slough, ⁸Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) require effective treatment across all symptoms. Bimekizumab (BKZ) is a humanized IgG1 monoclonal antibody which selectively neutralizes interleukin…
Abstract Number: 0907 • ACR Convergence 2020
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Laura Coates¹, Dafna Gladman², Filip Van den Bosch³, Philip Helliwell⁴, Anna Rychlewska-Hańczewska⁵, Mykola Stanislavchuk⁶, Leen Gilles⁷, Lien Gheyle⁷, Ke Liu⁸, Mona Trivedi⁸, Muhsen Alani⁹, Robin Besuyen¹⁰ and Philip Mease¹¹, ¹University of Oxford, Oxford, United Kingdom, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ghent University Hospital, Ghent, Belgium, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Ai Centrum Medyczne, Poznań, Poland, ⁶National Pirogov Memorial Medical University, Vinnytsya, Ukraine, ⁷Galapagos NV, Mechelen, Belgium, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc. and University of Washington, Foster City, CA, ¹⁰Galapagos BV, Leiden, Netherlands, ¹¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…
Abstract Number: 0908 • ACR Convergence 2020
Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Atul Deodhar¹, Philip Mease², Wolf-Henning Boehncke³, John Tesser⁴, Elena Schiopu⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, May Shawi¹⁰, Yusang Jiang¹¹, Shihong Sheng¹¹, Prasheen Agarwal¹¹, Joseph Merola¹², Iain McInnes¹³ and Christopher Ritchlin¹⁴, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Geneva University Hospitals, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Michigan Medicine, Ann Arbor, MI, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Global Services, LLC, Toronto, ON, Canada, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ¹³Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ¹⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the IL-23p19-subunit, has shown consistent efficacy in psoriasis pts regardless of body weight/body mass index (BMI).1 GUS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].